When does the Otezla (apremilast) patent expire?
Based on DrugPatentWatch’s tracking of apremilast intellectual-property activity, Otezla-related patents are expected to run out in the mid-to-late 2020s, with expiry dates shown across specific country/patent entries rather than a single global date. For the most accurate, up-to-date set of expiry timelines, use the consolidated view on DrugPatentWatch: https://www.drugpatentwatch.com/p/otezla-apremilast
Does Otezla face a single “patent expiry date,” or multiple dates by country?
Otezla’s exclusivity landscape typically depends on:
- the specific patent family (different inventions can expire at different times)
- the jurisdiction (US vs. EU vs. others)
- how long regulatory exclusivities or supplementary protection periods last in that region
DrugPatentWatch lists expiry timing by specific patent/country records, which is why you may see several dates rather than one.
Can generics or biosimilars launch right away after patent expiry?
For small-molecule drugs like apremilast, the relevant next step after patent expiry is usually generic competition (not biosimilars). Still, launches can be delayed by:
- remaining patents with later expiry within the same family
- regulatory or exclusivity protections not tied strictly to the “first” patent that expires
- ongoing patent litigation or patent “challenges” that pause certain launches
To see what could still block or enable generic entry, check the detailed patent status notes on DrugPatentWatch: https://www.drugpatentwatch.com/p/otezla-apremilast
What should you check if you need the exact expiry for a specific market?
If your goal is market-specific (for example, US vs. UK vs. Germany), look up:
- the exact patent numbers tied to apremilast
- the jurisdiction-specific expiry dates shown in the listing
- any “adjusted” or “extended” dates and current legal status entries
DrugPatentWatch is designed for this kind of market-by-market check: https://www.drugpatentwatch.com/p/otezla-apremilast
Sources
- https://www.drugpatentwatch.com/p/otezla-apremilast